Pricing
Login
Home
Charts
Search
Watchlist
Products

Asston Pharmaceuticals Ltd

APL
₹161.70-0.06%20 Nov 2026
Reports
Pharma Formulations

Asston Pharmaceuticals Ltd

APL
₹161.70
-0.06%
20 Nov 2026
Ask AI
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹177Cr
Close
Close Price
₹161.70
Industry
Industry
Pharma Formulations
PE
Price To Earnings
33.41
PS
Price To Sales
6.98
Revenue
Revenue
₹25Cr
Rev Gr TTM
Revenue Growth TTM
3.39%
PAT Gr TTM
PAT Growth TTM
-29.64%

Quarterly Results

Standalone
Numbers
Percentage
QuarterSep 2024Mar 2025Sep 2025Mar 2026Sep 2026
Revenue
RevenueCr
169151015
Growth YoY
Revenue Growth YoY%
-3.410.8-1.0
Expenses
ExpensesCr
146131312
Operating Profit
Operating ProfitCr
232-33
OPM
OPM%
14.235.114.5-27.922.3
Other Income
Other IncomeCr
10152
Interest Expense
Interest ExpenseCr
01000
Depreciation
DepreciationCr
00000
PBT
PBTCr
23315
Tax
TaxCr
11011
PAT
PATCr
22303
Growth YoY
PAT Growth YoY%
77.9-75.4-3.3
NPM
NPM%
11.921.521.94.821.4
EPS
EPS₹
3.03.19.31.13.7
QuarterSep 2024Mar 2025Sep 2025Mar 2026Sep 2026
Revenue
RevenueCr
169151015
Growth YoY
Revenue Growth YoY%
-3.410.8-1.0
Expenses
ExpensesCr
146131312
Operating Profit
Operating ProfitCr
232-33
OPM
OPM%
14.235.114.5-27.922.3
Other Income
Other IncomeCr
10152
Interest Expense
Interest ExpenseCr
01000
Depreciation
DepreciationCr
00000
PBT
PBTCr
23315
Tax
TaxCr
11011
PAT
PATCr
22303
Growth YoY
PAT Growth YoY%
77.9-75.4-3.3
NPM
NPM%
11.921.521.94.821.4
EPS
EPS₹
3.03.19.31.13.7

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
10716252525
Growth
Revenue Growth%
-31.9138.460.61.73.4
Expenses
ExpensesCr
10513202625
Operating Profit
Operating ProfitCr
0235-11
OPM
OPM%
-3.723.216.321.7-2.22.4
Other Income
Other IncomeCr
110166
Interest Expense
Interest ExpenseCr
011111
Depreciation
DepreciationCr
000001
PBT
PBTCr
012556
Tax
TaxCr
000112
PAT
PATCr
011444
Growth
PAT Growth%
855.328.7183.20.3-29.6
NPM
NPM%
1.116.28.715.415.214.8
EPS
EPS₹
11.61.92.46.14.94.8
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
10716252525
Growth
Revenue Growth%
-31.9138.460.61.73.4
Expenses
ExpensesCr
10513202625
Operating Profit
Operating ProfitCr
0235-11
OPM
OPM%
-3.723.216.321.7-2.22.4
Other Income
Other IncomeCr
110166
Interest Expense
Interest ExpenseCr
011111
Depreciation
DepreciationCr
000001
PBT
PBTCr
012556
Tax
TaxCr
000112
PAT
PATCr
011444
Growth
PAT Growth%
855.328.7183.20.3-29.6
NPM
NPM%
1.116.28.715.415.214.8
EPS
EPS₹
11.61.92.46.14.94.8
Sales CAGR
1 Year2%
3 Years57%
5 Years-
TTM-
PAT CAGR
1 Year1%
3 Years54%
5 Years-
TTM-
Avg. ROCE
1 Year12%
3 Years22%
5 Years22%
TTM9%
CFO / EBITDA
1 Year-
3 Years-191%
5 Years-183%
TTM-

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
1116911
Reserves
ReservesCr
01653059
Current Liabilities
Current LiabilitiesCr
81012159
Non Current Liabilities
Non Current LiabilitiesCr
12224
Total Liabilities
Total LiabilitiesCr
91420285283
Current Assets
Current AssetsCr
711182741
Non Current Assets
Non Current AssetsCr
232111
Total Assets
Total AssetsCr
91420285283
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
1116911
Reserves
ReservesCr
01653059
Current Liabilities
Current LiabilitiesCr
81012159
Non Current Liabilities
Non Current LiabilitiesCr
12224
Total Liabilities
Total LiabilitiesCr
91420285283
Current Assets
Current AssetsCr
711182741
Non Current Assets
Non Current AssetsCr
232111
Total Assets
Total AssetsCr
91420285283

Cash Flow

Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-10-40-10
Investing Cash Flow
Investing Cash FlowCr
0-101-10
Financing Cash Flow
Financing Cash FlowCr
114-121
Net Cash Flow
Net Cash FlowCr
00001
Free Cash Flow
Free Cash FlowCr
-1-1-41-20
CFO To PAT
CFO To PAT%
-1,072.6-29.9-291.8-0.7-263.4
CFO To EBITDA
CFO To EBITDA%
333.7-20.8-155.9-0.51,800.7
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-10-40-10
Investing Cash Flow
Investing Cash FlowCr
0-101-10
Financing Cash Flow
Financing Cash FlowCr
114-121
Net Cash Flow
Net Cash FlowCr
00001
Free Cash Flow
Free Cash FlowCr
-1-1-41-20
CFO To PAT
CFO To PAT%
-1,072.6-29.9-291.8-0.7-263.4
CFO To EBITDA
CFO To EBITDA%
333.7-20.8-155.9-0.51,800.7

Ratios

Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
62177
Price To Earnings
Price To Earnings
16.133.4
Price To Sales
Price To Sales
2.47.0
Price To Book
Price To Book
1.62.6
EV To EBITDA
EV To EBITDA
-116.7295.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
20.148.837.442.429.129.1
OPM
OPM%
-3.723.216.321.7-2.22.4
NPM
NPM%
1.116.28.715.415.214.8
ROCE
ROCE%
14.029.520.832.611.99.0
ROE
ROE%
11.953.221.334.99.95.4
ROA
ROA%
1.27.76.713.77.54.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
62177
Price To Earnings
Price To Earnings
16.133.4
Price To Sales
Price To Sales
2.47.0
Price To Book
Price To Book
1.62.6
EV To EBITDA
EV To EBITDA
-116.7295.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
20.148.837.442.429.129.1
OPM
OPM%
-3.723.216.321.7-2.22.4
NPM
NPM%
1.116.28.715.415.214.8
ROCE
ROCE%
14.029.520.832.611.99.0
ROE
ROE%
11.953.221.334.99.95.4
ROA
ROA%
1.27.76.713.77.54.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Market CapitalizationMkt CapCr205202198177154151151
Close PriceClose₹167.10160.7067.20161.7018.5492.00255.24
IndustryIndustryPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma Formulations
Price To EarningsPE20.600.282.7233.4111.249.4720.13
Price To SalesPS2.433.122.516.980.591.270.93
RevenueRevenueCr84657925259118162
Revenue Growth TTMRev Gr TTM%22.5%-14.9%3.4%50.8%7.5%24.2%
PAT Growth TTMPAT Gr TTM%33.6%421.4%-29.6%20.1%16.4%387.4%
Market CapitalizationMkt CapCr205202198177154151151
Close PriceClose₹167.10160.7067.20161.7018.5492.00255.24
IndustryIndustryPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma Formulations
Price To EarningsPE20.600.282.7233.4111.249.4720.13
Price To SalesPS2.433.122.516.980.591.270.93
RevenueRevenueCr84657925259118162
Revenue Growth TTMRev Gr TTM%22.5%-14.9%3.4%50.8%7.5%24.2%
PAT Growth TTMPAT Gr TTM%33.6%421.4%-29.6%20.1%16.4%387.4%
Annual Reports
FY2026
FY2025
Quarterly Reports
FY2026
Sep 26
Result
PPT
Transcript
Summary
Mar 26
Result
PPT
Transcript
Summary
Sep 25
Result
PPT
Transcript
Summary
Annual Reports
Quarterly Reports
Sep 26
Result
PPT
Transcript
Summary
Mar 26
Result
PPT
Transcript
Summary
Sep 25
Result
PPT
Transcript
Summary
Load More
Interviews